fashion -WSS

fashion

author：Wikipedia 2025-09-27 12:35:10 - browse：16184

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： India sets sights on home

WSS

The kidney, in all its complexity, is captured in a new atlas

TikTok cracks down on users posting about weight loss drugs

STAT Virtual Event: ASCO Recap, Live!

Plane’s emergency slide plummets from sky, hits Chicago home

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Lilly's Alzheimer's drug donanemab backed by FDA advisers

hotspot

fashion

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Plane’s emergency slide plummets from sky, hits Chicago home

How to save PrEP access — and even expand it

How faith leaders like me can help address America's obesity epidemic

Apple is now the first public company to be valued at $3 trillion

California wildfire smoke linked to 52,000 early deaths, study says

After affirmative action ruling, medical educators look to 'holistic review'

Statins may not be needed by millions of people, study suggests

DIEP, the 'gold standard' of breast reconstruction, is under threat

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

entertainment

Medical experts are missing from AI regulatory conversations

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Seattle police shoot person suspected in downtown stabbing

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Lilly's Alzheimer's drug donanemab backed by FDA advisers

New warning issued for rebooking air travel after delays, cancellations

Wikipedia

focus

focus

hotspot